Ticker: CMPX

Compass Therapeutics, Inc. (NASDAQ: CMPX) - Q2 2025 snapshot Straight to the point: clinical progress is driving higher R&D spending. The company has a solid cash and securities position today but is burning cash faster year‑over‑year. Key trial readouts and program milestones are the main near‑t...